EAM
AZN icon

EverPoint Asset Management’s AstraZeneca AZN Stock Holding History

EverPoint Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$32.8M Buy
600,000
+500,000
+500% +$28.4M 0.61% 40
2016
Q3 		$6.57M Sell
100,000
-50,000
-33% -$3.27M 0.12% 207
2016
Q2 		$9.06M Buy
+150,000
New +$8.71M 0.18% 158

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

EverPoint Asset Management's AZN Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in AstraZeneca (AZN) in Q4 2016: 300,000 shares worth $16.4M. The stake represents 0.3% of the portfolio and ranks #87 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in AZN as recently as Q1 2015.

EverPoint Asset Management first reported a position in AZN in Q2 2014 and has held it in 5 quarters since. The position peaked at $19.3M in Q2 2014. 449 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

  • EverPoint Asset Management held 300,000 shares of AstraZeneca worth $16.4M as of Q4 2016.
  • AstraZeneca was a new EverPoint Asset Management position in Q4 2016.
  • AstraZeneca made up 0.3% of EverPoint Asset Management's portfolio in Q4 2016, its #87 holding.
  • EverPoint Asset Management first reported a position in AstraZeneca in Q2 2014 and has held it in 5 quarters since.
  • EverPoint Asset Management's AstraZeneca position peaked at $19.3M in Q2 2014.
  • 449 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.